Skip to content

Clinical trials

Leukemia, Myeloid, Acute trials in Italy with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Phase: Not applicable Country / region: Italy Clear all

12 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20171
20201
20212
20223
20231
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting6
Completed2
Unknown status2
Active, not recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Gruppo Italiano Malattie EMatologiche dell'Adulto3
Advice Pharma Group srl1
Azienda Ospedaliero-Universitaria di Parma1
European Institute of Oncology1
European Organisation for Research and Treatment of Cancer - EORTC1
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1
Fred Hutchinson Cancer Center1
IRCCS Azienda Ospedaliero-Universitaria di Bologna1
University Of Perugia1
University of Milano Bicocca1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute12
Hodgkin Disease4
Precursor Cell Lymphoblastic Leukemia-Lymphoma4
Leukemia, Lymphocytic, Chronic, B-Cell3
Lymphoma, Non-Hodgkin3
Multiple Myeloma3
Myeloproliferative Disorders3
Anemia, Refractory, with Excess of Blasts2
Burkitt Lymphoma2
Congenital Abnormalities2

Trials

Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.